DK1583830T3 - Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner - Google Patents

Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner

Info

Publication number
DK1583830T3
DK1583830T3 DK04700438T DK04700438T DK1583830T3 DK 1583830 T3 DK1583830 T3 DK 1583830T3 DK 04700438 T DK04700438 T DK 04700438T DK 04700438 T DK04700438 T DK 04700438T DK 1583830 T3 DK1583830 T3 DK 1583830T3
Authority
DK
Denmark
Prior art keywords
cells
collection
library
nucleic acid
recombinant polyclonal
Prior art date
Application number
DK04700438T
Other languages
English (en)
Inventor
John S Haurum
Finn C Wiberg
Jacqueline Sharon
Chiou-Ying Yang
Vincent W Coljee
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Application granted granted Critical
Publication of DK1583830T3 publication Critical patent/DK1583830T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
DK04700438T 2003-01-07 2004-01-07 Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner DK1583830T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43840303P 2003-01-07 2003-01-07
DKPA200300008 2003-01-07
US47601803P 2003-06-05 2003-06-05
PCT/DK2004/000001 WO2004061104A2 (en) 2003-01-07 2004-01-07 Method for manufacturing recombinant polyclonal proteins

Publications (1)

Publication Number Publication Date
DK1583830T3 true DK1583830T3 (da) 2007-01-15

Family

ID=32718469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04700438T DK1583830T3 (da) 2003-01-07 2004-01-07 Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner

Country Status (18)

Country Link
US (1) US9163232B2 (da)
EP (2) EP1583830B1 (da)
JP (2) JP4589914B2 (da)
KR (1) KR101024443B1 (da)
AT (1) ATE338816T1 (da)
AU (1) AU2004203727C1 (da)
BR (1) BRPI0406678A (da)
CA (1) CA2512647C (da)
DE (1) DE602004002275T2 (da)
DK (1) DK1583830T3 (da)
EA (1) EA013225B1 (da)
ES (1) ES2273202T3 (da)
IL (1) IL169101A (da)
MX (1) MXPA05006724A (da)
NZ (1) NZ541458A (da)
PT (1) PT1583830E (da)
SI (1) SI1583830T1 (da)
WO (1) WO2004061104A2 (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
PL1787126T3 (pl) * 2004-07-20 2010-03-31 Symphogen As Sposób charakteryzowania poliklonalnej linii komórkowej
MX2007000644A (es) * 2004-07-20 2007-03-28 Symphogen As Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
MX2008011280A (es) * 2006-03-06 2008-09-12 Symphogen As Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio.
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
JP5669397B2 (ja) 2007-03-01 2015-02-12 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 同族抗体をクローニングするための方法
NZ597466A (en) 2007-03-01 2013-08-30 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions
MX2009009226A (es) * 2007-03-06 2009-10-28 Symphogen As Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
HRP20100640T1 (hr) * 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US8546540B2 (en) 2007-10-11 2013-10-01 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein Siglec-15
CA2722348A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
EP2331577B1 (en) 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2010022738A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
MX2011007342A (es) 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
CN102596248A (zh) 2009-10-15 2012-07-18 艾瓦夏生物制剂公司 在消化道中具有局部活性的抗体治疗剂
NZ610153A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
DK2640743T3 (da) 2010-11-16 2017-01-23 Excelimmune Inc Fremgangsmåder til fremstilling af rekombinante proteiner
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
HRP20200744T1 (hr) 2011-12-22 2020-07-24 F. Hoffmann - La Roche Ag Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
HK1204657A1 (en) 2012-03-30 2015-11-27 Daiichi Sankyo Company, Limited Anti-siglec15 antibody with modified cdr
HK1204797A1 (en) 2012-03-30 2015-12-04 Daiichi Sankyo Company, Limited Novel anti-siglec15 antibody
CN104334724B (zh) 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
KR20190020838A (ko) 2012-04-27 2019-03-04 다이이찌 산쿄 가부시키가이샤 항-robo4 항체
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
JP2015163047A (ja) * 2012-06-20 2015-09-10 国立大学法人 東京大学 タンパク質の迅速改良法
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
SG11201602490UA (en) 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Anti-lps o11 antibody
US9931401B2 (en) 2013-10-08 2018-04-03 Daiichi Sankyo Company, Limited Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor
WO2015093925A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Isaac Método de producción de anticuerpos específicos
SMT202500020T1 (it) 2014-02-28 2025-03-12 Merus Nv Anticorpo che lega erbb-2 ed erbb-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
CN107530427A (zh) 2015-03-27 2018-01-02 南加利福尼亚大学 针对用于实体肿瘤的治疗的lhr的car t细胞疗法
EP3302559B1 (en) 2015-06-04 2022-01-12 University of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
KR20180053744A (ko) 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 면역 요법을 위한 flt3 유도된 car 세포
EP4349997A3 (en) 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anti-garp antibody
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
JP7301540B2 (ja) * 2016-05-26 2023-07-03 チールー ピュージェット サウンド バイオセラピューティクス コーポレイション 抗体の混合物
ES3039621T3 (en) 2016-12-22 2025-10-23 Daiichi Sankyo Co Ltd Anti-cd3 antibody, and molecule containing said antibody
RU2019128134A (ru) 2017-02-07 2021-03-09 Дайити Санкио Компани, Лимитед Антитело против gprc5d и молекула, содержащая антитело
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
KR102737715B1 (ko) 2017-04-05 2024-12-03 르 라보레또레 쎄르비에르 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
JP7181535B2 (ja) 2017-06-30 2022-12-01 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
EP3660155A4 (en) 2017-07-27 2021-04-07 Daiichi Sankyo Company, Limited ANTI-CD147 ANTIBODY
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
TW201927336A (zh) 2017-10-05 2019-07-16 日商第一三共股份有限公司 細胞毒性ｔ細胞耗竭用組成物
CA3084315A1 (en) 2017-12-11 2019-06-20 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
EP3763386A4 (en) 2018-03-05 2021-12-29 Saitama Medical University Pharmaceutical composition for treating or preventing heterotopic ossification
TWI833761B (zh) 2018-05-31 2024-03-01 日商第一三共股份有限公司 抗人類ｔｌｒ７抗體以及其製造方法及用途
EP3810649A1 (en) * 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
KR102816742B1 (ko) 2018-07-10 2025-06-05 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP2022531113A (ja) 2019-04-30 2022-07-06 ギガジェン，インコーポレイティッド 組換えポリクローナルタンパク質およびその使用方法
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
JPWO2021079958A1 (da) 2019-10-25 2021-04-29
US20240042002A1 (en) 2019-12-31 2024-02-08 Antagonis Compositions and methods for the prevention of S. aureus infection
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) * 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
US11975066B2 (en) 2020-08-31 2024-05-07 SAB Biotherapeutics, Inc. Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
IL324556A (en) 2023-05-19 2026-01-01 Servier Lab Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155114A (en) * 1874-09-15 Improvement in methods of laying and forming cast-iron pipes
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
EP0530216A4 (en) 1990-04-19 1993-06-30 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
PT744958E (pt) * 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
BR9808584A (pt) * 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US6368821B1 (en) * 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US20020155114A1 (en) 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2373690A1 (en) 1999-07-14 2001-01-25 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
AU6364800A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system
EP1283720B1 (en) * 2000-05-26 2007-04-18 Symphogen A/S Recombinant or purified polyclonal antibodies for treating allergy
EP1293564A4 (en) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp EXPRESSION VECTOR FOR SCREENING CELLS HIGH EXPRESSION OF RECOMBINANT PROTEINS, TRANSFORMING HIGH EXPRESSION OF A RECOMBINANT PROTEIN AND USE THEREOF
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
EP1337631A2 (en) * 2000-11-28 2003-08-27 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
US20030044398A1 (en) * 2001-03-20 2003-03-06 Robl James M. Methods for producing antibodies in mammals
EP2314629B2 (en) * 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
AU2003283995A1 (en) 2002-09-30 2004-04-19 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
PL1787126T3 (pl) 2004-07-20 2010-03-31 Symphogen As Sposób charakteryzowania poliklonalnej linii komórkowej
MX2007000644A (es) * 2004-07-20 2007-03-28 Symphogen As Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
MX2008011280A (es) 2006-03-06 2008-09-12 Symphogen As Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio.
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
HRP20100640T1 (hr) 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina

Also Published As

Publication number Publication date
CA2512647C (en) 2013-10-08
ATE338816T1 (de) 2006-09-15
US20090136498A1 (en) 2009-05-28
EP1583830B1 (en) 2006-09-06
HK1078896A1 (en) 2006-03-24
BRPI0406678A (pt) 2005-12-20
AU2004203727A1 (en) 2004-07-22
JP2006515520A (ja) 2006-06-01
KR101024443B1 (ko) 2011-03-23
PT1583830E (pt) 2006-11-30
WO2004061104A3 (en) 2004-11-04
EA200501101A1 (ru) 2006-02-24
AU2004203727B2 (en) 2008-01-31
EP1583830A2 (en) 2005-10-12
KR20050101538A (ko) 2005-10-24
NZ541458A (en) 2006-04-28
ES2273202T3 (es) 2007-05-01
DE602004002275D1 (de) 2006-10-19
DE602004002275T2 (de) 2007-09-06
MXPA05006724A (es) 2005-09-08
WO2004061104A2 (en) 2004-07-22
IL169101A (en) 2009-02-11
US9163232B2 (en) 2015-10-20
EA013225B1 (ru) 2010-04-30
JP4589914B2 (ja) 2010-12-01
AU2004203727C1 (en) 2008-08-21
CA2512647A1 (en) 2004-07-22
JP2010268806A (ja) 2010-12-02
EP1762617A1 (en) 2007-03-14
SI1583830T1 (sl) 2006-12-31

Similar Documents

Publication Publication Date Title
EA200501101A1 (ru) Способ получения рекомбинантных поликлональных белков
EA200700249A1 (ru) Рекомбинантное поликлональное антитело против резус-фактора d и способы его получения
DK2152872T3 (da) Fremgangsmåde til fremstilling af et rekombinant polyklonalt protein
US12024548B2 (en) Rapid method for cloning and expression of cognate antibody variable gene segments
Kurosawa et al. Rapid production of antigen-specific monoclonal antibodies from a variety of animals
CN105602960A (zh) 抗体的快速人源化
JP2015503907A (ja) 真核細胞のための全長抗体提示システムおよびその使用
DE60039596D1 (de) Verfahren zur herstellung von monoklonalen antikörpern
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
KR20240130125A (ko) 항-gprc5d 항체 및 그의 응용
Price et al. Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas
CN111093696A (zh) 抗iii型纤连蛋白结构域的抗原结合区及其使用方法
CN118339304A (zh) 克隆的中国仓鼠卵巢细胞及其用途
US20190031752A1 (en) Method for Producing Antibodies
CN120239745B (zh) 永生化细胞的制造方法
EP2238155A2 (en) Cynomolgus toll-like receptor 3
MX2024006573A (es) Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15.
Lee et al. Increasing hybridoma viability and antibody repertoire after the cell fusion by the use of human plasma as an alternative supplement